Base Therapeutics (Shanghai) Co., Ltd.
Quick facts
Phase 1 pipeline
- NK510
- NK510 : allogeneic genetic modified NK
- NK520
- Tislelizumab，atezolizumab or sugemalimab
- Tislelizumab，atezolizumab or Trastuzumab
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: